Corticotropin (ACTH)-independent macronodular adrenal hyperplasia (AIMAH) is a heterogeneous condition in which cortisol secretion may be mediated by gastrointestinal peptide (GIP), vasopressin, catecholamines and other hormones. We studied the expression profile of AIMAH by genomic cDNA microarray analysis. Total RNA was extracted from eight tissues (three GIP-dependent) and compared to total RNA obtained from adrenal glands from 62 normal subjects. Genes had to be altered in 75% of the patients, and be up-or downregulated at a cutoff ratio of at least 2.0; 82 and 31 genes were found to be consistently up-and downregulated, respectively. Among the former were regulators of transcription, chromatin remodeling, and cell cycle and adhesion. Downregulated sequences included genes involved in immune responses and insulin signaling. Hierarchical clustering correlated with the two main AIMAH diagnostic groups: GIPdependent and non-GIP-dependent. The genes encoding the 7B2 protein (SGNE1) and WNT1-inducible signaling pathway protein 2 (WISP2) were specifically overexpressed in the GIP-dependent AIMAH. For these, and six more genes, the data were validated by semiquantitative amplification in samples from a total of 32 patients (the original eight, six more cases of AIMAH, and 18 other adrenocortical hyperplasias and tumors) and the H295R adrenocortical cancer cell line. In conclusion, our data confirmed AIMAH's clinical heterogeneity by identifying molecularly distinct diagnostic subgroups. Several candidate genes that may be responsible for AIMAH formation and/or progression were also identified, suggesting pathways that affect the cell cycle, adhesion and transcription as possible mediators of adrenocortical hyperplasia.
Introduction
The clinical and molecular genetic profile of adrenocortical cancer (ACC), a rare disorder, has been extensively studied (Kjellman et al., 1996; Figueiredo et al., 1999; Zhao et al., 1999; Sidhu et al., 2002) . A number of alterations have been detected at the DNA or protein levels (Koch et al., 2000; Giordano et al., 2003) , which are, however, presumed to be secondary and/or tertiary events responsible for tumor initiation (Stratakis, 2003) . If one accepts the multistep model of carcinogenesis that has been proposed for other tumor types (Fearon and Vogelstein, 1990; Bornstein et al., 1999) , the genetic analysis of primary adrenocortical hyperplasia would be more informative for the identification of the initial and specific events leading to adrenocortical tumor (ACT) formation. Indeed, albeit rarely, ACC forms in the background of hyperplasia, as in patients with 21-hydroxylase deficiency (Hamwi et al., 1957; Pang et al., 1981; Bauman and Bauman, 1982) . More frequently, adenomas form in hyperplastic adrenal glands, such as those of patients with multiple endocrine neoplasia type 1 (MEN 1) (Skogseid et al., 1992) , McCune-Albright syndrome (Boston et al., 1994) and Carney complex . In these conditions, the molecular defects are well characterized (Weinstein et al., 1991; Chandrasekharappa et al., 1997; Kirschner et al., 2000) but, only infrequently (if ever), MEN1, GNAS1 or PRKAR1A mutations occur in sporadic ACTs (Reincke et al., 1993 Heppner et al., 1999; Zwermann et al., 2000; Bertherat et al., 2002) .
We hypothesized that by studying the corticotropin (ACTH)-independent form of macronodular adrenal hyperplasia (AIMAH), we could potentially identify novel genetic mechanisms acting early in adrenal tumorigenesis. AIMAH, a rare disorder, is often (but not always) associated with classic and atypical forms of Cushing syndrome (Mircescu et al., 2000; Bourdeau et al., 2001) . In a subgroup of patients, cortisol secretion is regulated by the aberrant adrenocortical expression of receptors for various hormones, such as those for gastric inhibitory polypeptide (GIP), vasopressin, b-adrenergic agonists, serotonin and LH/hCG .
To date, there have been no genomic studies of AIMAH tissues and/or cell lines. In our investigation, we used arrays containing more than 10 000 PCRamplified cDNA clones to study the expression profiles of AIMAH tissues from eight unrelated patients that were first clinically studied under a protocol, and compared it to a pool of total RNA from 62 normal adrenal glands. The gene array data for selected genes were confirmed by semiquantitative reverse transcriptase (RT)-PCR, first, in the eight AIMAH tissues that were studied by microarrays and, second, in an additional 24 tumors, including AIMAH, ACTHdependent adrenal hyperplasia, adrenocortical adenomas, a carcinoma and the cancer cell line H295R.
Results

Differential gene expression in AIMAH
To evaluate global changes in gene expression associated with the development of AIMAH, RNA samples from eight patients of AIMAH, who were first studied clinically (Table 1) , were compared against a pool of 62 normal adrenal glands. Selected genes had to be upor downregulated at a minimum of a twofold difference in expression values and in at least 6-8 AIMAH samples. Using these stringent criteria, 113 genes were identified: 82 genes were overexpressed and 31 were underexpressed (Tables 2 and 3, respectively) .
Genes meeting the criteria for overexpression are listed in Table 2 . Several of these genes encode proteins playing a role in cell cycle (activator of S phase kinase (ASK), cyclin G1 (CCNG1), cyclin-dependent kinase 7 (CDK7)), chromatin remodeling (histone acetyltransferase 1 (HAT1), H1 histone family, member X (H1FX)), regulation of transcription (hypoxia-inducible factor 1 a-subunit (HIF1A), transcriptional intermediary factor 1 (TIF1), CCAAT-box-binding transcription factor (CBF2)) and cell adhesion (pinin (PNN), ras homolog gene family member E (ARHE), catenin (cadherinassociated protein)-a-like 1 (CTNNAL1)). Some of these genes, such as breast carcinoma-amplified sequence 2 (BCAS2), serologically defined colon cancer antigen 1 (SDCCAG1) and meningioma-expressed antigen 6 (MGEA6), are known to be aberrantly expressed in cancers. Most of these genes were not known to have a role in adrenal tumorigenesis or even be expressed in adrenocortical tissue.
The underexpressed genes are listed in Table 3 . Four genes corresponding to known transcripts derived from the medulla, such as tyrosine hydroxylase (TH), cocaineand amphetamine-regulated transcript (CART), dopamine beta-hydroxylase (DBH) and proenkephalin (PENK), were significantly underexpressed in AIMAH samples. This finding most likely reflects the nature of our specimens (adrenocortical tissue) versus that of the reference RNA (total adrenoglandular RNA). It is noteworthy that several immunoglobulin genes and others involved in lipid metabolism and the insulin signaling pathway were also downregulated (Table 3) .
Five genes were chosen among this data set for RT-PCR validation (see below) based on their degree of involvement (fold-of-difference, Tables 2 and 3) or known significance for ACT formation: three overexpressed genes -the kinesin family member 5B (KIF5B), the CTNNAL1 and the HIF1A -and two underexpressed genes -the insulin-like growth factor type II (IGF-II, the IGF2 gene) and carboxypeptidase E (CPE). These two sequences were consistently and significantly underexpressed in AIMAH samples but not in the one carcinoma studied by microarray (data not shown).
Genes differentially expressed between AIMAH diagnostic groups
Considering that three of the patients that were studied showed a distinct clinical profile (GIP-or fooddependent AIMAH, Table 1 ), we performed cluster analysis of the data set, in which we sought to identify gene expression in three of the eight samples (the GIP-AIMAH group). With this analysis, we identified a total of 778 genes, including several that were not present in the first data set and were overexpressed such as some that are known to have a role in adrenal tumorigenesis like cyclin-dependent kinase inhibitor 1C (p57, Kip2), the gap junction protein, alpha 1, 43 kDa (connexin 43), and the regulatory subunit type-2B of protein kinase A (PKA) (PRKAR2B). Genes that were underexpressed included those that encode molecules involved in adrenal steroidogenesis including cytochrome P450 enzymes, such as CYP11A (cholesterol side-chain cleavage), CYP17 (17-a-hydroxylase) and CYP21A2.
Hierarchical clustering of this analysis showed a distinct clustering of the GIP-dependent AIMAH relative to the non-GIP AIMAH. Data from patients with GIP-dependent AIMAH placed them under a unique subdivision of the branches that reflect geneexpression similarities, when compared to the other patients with AIMAH ( Figure 1 ). It should be noted that these patients were the first ones to be identified as those with unexpected, 'neuroendocrine' responses (Lacroix et al., 1992; Reznik et al., 1992) and appear to have unique clinical features (Table 1) . Among the genes that were overexpressed in GIP-dependent but not in GIP-nondependent AIMAH were genes encoding the WNT1-inducible signaling pathway protein 2 (WISP2), the neuroendocrine protein 1 (SGNE1) and a member of the RAS oncogene family (RAB31) that were validated by RT-PCR (see below).
Validation of differential expression using RT-PCR
We selected eight genes from the list of genes that were differentially regulated for validation by RT-PCR analysis. Overall, our RT-PCR data agreed well with microarray data. For example, the genes encoding the kinesin family member 5B (KIF5B) and CNNAL1 (Table 2) were overexpressed in all 14 AIMAH tissues (eight that were included in the microarray experiments, and an additional six samples) with a significant increase of 5.871.5-and 3.170.7-fold, respectively, relative to normal adrenoglandular RNA (Figure 2 ). KIF5B was overexpressed in ACTH-dependent adrenal hyperplasia (6.073.0), adrenocortical adenomas (3.771.2) and cancer (3.1), and by 11.1-fold in the H295R cell line (Figure 2a) . Similarly, CNNAL1 was overexpressed in 
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Figure 2 Mean expression ratio of KIF5B (a), CNNAL1 (b), HIF1A (c), CPE (d) and IGF2 (e) by multiplex RT-PCR in normal adrenal glands (NA), ACTH-dependent adrenal hyperplasia (ADH), ACTH-independent macronodular adrenal hyperplasia (AIMAH), adrenal adenomas, cancer and the H295R human adrenocortical carcinoma cell line. Expression of IGF2 was not significantly altered overall in AIMAH compared to normal adrenal (NA), whereas IGF2 was clearly highly expressed in both cancer and the H295R cell line; there was, however, significant heterogeneity in the data set (see text). Errors bars represent standard error of the mean; *significance at Po0.05
ACTH-dependent adrenal hyperplasia (1.970.7), adenomas (2.870.6) and the H295R cell line (3.6), but not in the single carcinomatous tissue studied (1.1) (Figure 2b ). H1F1A was overexpressed by 1.570.2-fold in AI-MAH (Figure 2c) , consistent with its overexpression detected by microarray (Table 2) . H1F1A was as highly expressed in ACTH-dependent adrenal hyperplasia (1.670.3) as it was in AIMAH, but normally expressed in adenomas (1.270.2), and somewhat underexpressed in cancer and the H295R cell line (0.9 and 0.8, respectively).
Underexpression of CPE was also confirmed: its expression by RT-PCR was 0.670.1 (Figure 2d ) and 0.370.02 by microarray (Table 3 ). In addition, CPE was underexpressed in all samples, with the exception of cancer (1.1).
For one gene, IGF2, the RT-PCR and microarray data were slightly discordant for the entire data set, even though not for the individual samples, reflecting, perhaps, once more heterogeneity. In the 14 AIMAH tissues, RT-PCR showed a mean expression ratio of 1.170.08 compared to control RNA (Figure 2e ). In patients studied by microarrays, this technique showed an almost ninefold repression of IGF2 (Table 3) , whereas RT-PCR as a whole did not confirm this. However, the data were highly heterogeneous: in five, there was downregulation of IGF2 expression at about 80% or less; in two, there was even an increase in expression by RT-PCR (data not shown). IGF2 was clearly highly expressed in cancer (Figure 2e ) by RT-PCR, as previously described, and as we have seen in our cancer microarray data set (data not shown).
Differential gene expression in GIP-dependent AIMAH by RT-PCR
RT-PCR confirmed that WISP2 transcription was increased in the seven samples from GIP-dependent AIMAH by a mean of 5.471.3, but not in the other seven samples from non-GIP-dependent AIMAH (0.770.1) (P ¼ 0.01) (Figure 3a ). Higher expression of WISP2 was present in five out of seven GIP-dependent AIMAH tissues with a mean of 7.5-fold among the overexpressing tissues. There were no significant changes of WISP2 expression in ACTH-dependent hyperplasia (0.970.3) (P ¼ 0.05), adenomas (0.870.2) (P ¼ 0.003) or cancer (0.270.06) (P ¼ 0.15).
SGNE1 mRNA was also significantly increased in GIP-dependent AIMAH by 5.371.6 compared to normal adrenoglandular RNA, but not in non-GIPdependent AIMAH (0.670.05) (P ¼ 0.01), ACTHdependent hyperplasia (0.770.1) (P ¼ 0.03), adrenocortical adenomas (1.270.5) (P ¼ 0.009) and cancer (0.5) (P ¼ 0.1) (Figure 3b ). Looking at the individual tissues, SGNE1 was overexpressed in five out of seven GIP-dependent AIMAH samples with a mean change of 6.8-fold. Among the other tumors (see also below), one aldosterone-producing adenoma (which often has a 'neuroendocrine' differentiation) showed also significantly increased expression of SGNE1 (by 8.8-fold).
Finally, RAB31 mRNA transcription was 1.570.4-fold increased by RT-PCR in GIP-dependent AIMAH but not in non-GIP-dependent AIMAH (1.170.4) (P ¼ 0.1) (Figure 3c ). Increased expression was also observed in ACTH-dependent hyperplasia (1.470.4) (P ¼ 0.6), but not in adrenocortical adenomas (0.970.8) (P ¼ 0.02) or cancer (1.170.2) (P ¼ 0.3).
Discussion
In this study, we used cDNA microarray to explore variations in gene expression between a unique form of macronodular adrenal hyperplasia (AIMAH) and normal adrenal glands. We found altered expression of genes that were not known to play a significant role or even be expressed in adrenal cortex. One such example is the gene that codes for hypoxia-inducible factor 1 (HIF1A), a significant transcription factor that controls the expression of a variety of other molecules that are known to have a function in adrenocortical tumorigenesis such as IGF2, transforming growth factor b3 (TGFB3) and vascular endothelial growth factor (VEGF) (Semenza, 2000) . A previous report showed that very little expression of HIF1A was present in normal adrenal tissue (Talks et al., 2000) . Our data showed significant expression of HIF1A not only in AIMAH, but also in ACTH-induced hyperplasia, as well as its downregulation in cancer (Figure 2a) . Our dataset provides a gene list, which with its functional annotation opens new ways for the elucidation of the biological mechanisms leading to aberrantly functioning adrenocortical hyperplasia. Even though we used very stringent criteria in our microarray data analysis, which may have contributed to a gene list that may be shorter than expected, there is considerable new information and a number of molecular pathways that could now be the subject of further investigation.
The only gene expression information that was available so far for AIMAH was that of the aberrant presence of a variety of neuroendocrine molecules . These investigations were largely clinical and confirmed at the molecular level by RT-PCR studies; they had indicated that AIMAH was a heterogeneous group of adrenocortical hyperplasias. Indeed, this study of AIMAH patients with different clinical profiles (Table 1) confirmed heterogeneity ( Figure 1 ) and identified molecular pathways that may be associated with this functional diversity (see below).
Several lines of evidence indicate the validity of our analysis:
First, RT-PCR studies confirmed the microarray data for the genes that were checked by this method (Figures  2 and 3) .
Second, we selected from our gene list several other sequences that previous investigations had linked to adrenocortical tumorigenesis (in a candidate-gene approach) and compared this published information with the expression values generated by our microarray analysis (data not shown). One such example is that of the gene coding for the insulin-like growth factor binding protein-6 (IGFBP6), which in several adrenal tumors has been found to be underexpressed (Boulle et al., 1998) . This is true in our data also (Table 3) . Another sequence, IGF2, has been extensively discussed (Figure 2e ): RT-PCR confirmed its underexpression in some (but not all) AIMAH tissues and its overexpression in cancer.
Third, we did confirm downregulation of adrenal medulla-related genes because, first, AIMAH is of adrenocortical origin and, second, our 'reference' RNA was extracted from whole adrenoglandular tissue. This observation, even though adds some measure of confidence in the data presented herein, also underscores the possibility that for certain genes there might be an underestimation of their true level of adrenocortical expression. On the other hand, a gene with very little expression in medullary cells may appear somewhat overexpressed in the microarray data. However, we do not expect these variations to affect the bulk of the data presented in Table 2 , due to the stringency of our criteria.
We also looked for sequences that have been mapped on chromosomal areas that are known to be altered in ACTs. Indeed, chromosomal abnormalities such as chromosome gains and losses are a common feature of even benign adrenocortical adenomas, and certainly ACCs (Kjellman et al., 1996; Figueiredo et al., 1999; Zhao et al., 1999; Sidhu et al., 2002) . For example, comparative genomic hybridization (CGH) studies have revealed gain of chromosome 17 as an early event in ACT formation (Zhao et al., 1999) . We analysed the expression values of two genes that have been mapped to chromosome 17; both were indeed overexpressed: the 5 0 ,3 0 -nucleotidase, mitochondrial sequence (17p11.2) (Rampazzo et al., 2000) , and the solute carrier family 4, anion exchanger, member 1 (17q21-q22) (data not shown).
Finally, another finding in support of the presented data set is the downregulation of a certain group of genes on the basis of their physiological role. For example, two genes encoding enzymes involved in adrenal steroidogenesis (CYP11A, CYP17) were significantly downregulated. This may be a reflection of the low level of steroidogenesis of AIMAH cells, a fact that has been extensively discussed by other investigators and confirmed by immunohistochemistry studies . Although this finding sounds paradoxical in a condition associated with excess glucocorticoid production, the relative underexpression of these genes may underlie the known, in vivo, lowefficiency cortisol production in AIMAH compared to the volume of these tumors (Stratakis and Kirschner, 1998) ; it may also reflect diversion of the regular steroidogenic pathways toward enzymes that were not part of our gene set and may be responsible for the versatile steroid profile of AIMAH and other steroidproducing adrenal tumors (Suzuki et al., 1995; Kikuchi et al., 2000) . Accordingly, it is noteworthy that CYP21A2 was also among the sequences that were downregulated.
As mentioned earlier, AIMAH's clinical heterogeneity was confirmed by our finding of differential gene expression for at least one diagnostic group of patients, that of GIP-or food-dependent AIMAH. Patients with GIP-dependent AIMAH have classic symptoms of Cushing syndrome; however, in addition, their cortisol secretion is stimulated by meals due to the gastrointestinal release of GIP . In vivo, GIP infusion increases cortisol production in these patients, but not in normal controls (Lacroix et al., 1992) . Several investigators have demonstrated that the GIP receptors (a member of the G-protein-coupled receptors family) are overexpressed in adrenal adenoma or hyperplastic tissues from GIP-dependent CS compared to normal human adrenal cortex or non-GIP-dependent adrenal CS tissues (Lebrethon et al., 1998; N'Diaye et al., 1998) . Although, the molecular mechanisms underlying abnormal adrenocortical expression of GIP receptors remain unclear, the specific and significant overexpression of WISP2 in food-dependent AIMAH and that of catenin-a-like 1 (CTNNAL1) in all AIMAH tissues suggests a previously unsuspected involvement of these pathways in AIMAH formation. It is noteworthy that we not only showed that the WISP2 gene is significantly overexpressed in this group (Figure 3a) , but also found that a number of genes related to the WNT-1-b-catenin signaling were also altered in our data set (Table 2) .
WISP2 codes for the WNT1-inducible signaling pathway protein 2 and is located on 20q12-13. It is a member of the connective tissue growth factor/cysteinerich 61/nephroblastoma overexpressed (nov) (CCN) family and is upregulated in the mouse mammary epithelial cell line C57MG transformed by Wnt-1 (Pennica et al., 1998) , suggesting that WISP2 is a potential target for Wnt-1 regulation. Wnt-1 is a signaling pathway that mediates diverse developmental processes such as the control of cell proliferation and adhesion, and the establishment of cell fate (ConacciSorrell et al., 2002) and results in the activation of several tumor development-related genes, such as c-myc (He et al., 1998) and cyclin D1 (Tetsu and McCormick, 1999) . In 1998, Pennica et al. (1998) reported aberrant expression of WISP2 in human colon tumors, and more recently Saxena et al. (2001) showed higher expression of WISP2 mRNA in various breast tumor cell lines compared to human mammary epithelial cells.
Up to now, the Wnt pathway has not been studied in human adrenocortical tissue (Perbal, 2001 ). Interestingly, however, there is an increasing number of reported ACTs in association with familial adenomatous polyposis coli (FAP) due to germline mutations of the APC gene, which lead to activation of the Wnt-bcatenin signaling pathway (Marchesa et al., 1997; Wakatsuki et al., 1998; Kartheuser et al., 1999) . In addition, Heikkila et al. (2002) reported recently that lack of the Wnt-4 gene may lead to dysfunction of the adrenal cortex in Wnt-deficient mice.
Recently, Yamamoto et al. (2003) reported mRNA upregulation of Gpr49, an orphan G-protein-coupled receptor (GPCR), that was frequently present in hepatocellular carcinomas with mutations in b-catenin, suggesting that alterations of this pathway may lead to upregulation of GPCRs (such as, perhaps, the GIP receptor). In addition, other genes that may be affected by Wnt-1 signaling and were observed in the data set produced by the GIP-dependent AIMAH microarray analysis included the gap junction gene connexin43, a molecule that is also induced by Wnt-dependent increase of b-catenin in cardiomyocytes (Ai et al., 2000) (data not shown).
SGNE1, which was also specifically overexpressed in GIP-dependent AIMAH (Figure 3b ), codes for a neuroendocrine protein that regulates negatively ACTH secretion (Bergeron et al., 2002) and may lead to high levels of circulating ACTH and a Cushing syndromelike syndrome in 7B2-null mice (Westphal et al., 1999) .
An alternative explanation for specific gene overexpression in the GIP-AIMAH group would be sequence homology to the GIP receptors. However, a BLAST search using the WISP2 and SGNE1 cDNA sequence in the GenBank database did not reveal any significant homology (data not shown).
Other genes that we also found with significant overexpression and that we confirmed by RT-PCR were CTNNAL1 and KI5B (Figure 2) . The catenin (cadherin-associated protein), alpha-like 1 (CTNNAL1) or a-catulin gene shares strong homology with aEcatenin, a component of the E-cadherin/catenin cell adhesion complex. aE-catenin may bind to b-catenin, and link cadherin to actin cytoskeleton (Zhang et al., 1998; Janssens et al., 1999) . Recently, Park et al. (2002) described a distinct role for CTNNAL1 in modulating the Rho signaling pathway. CTNNAL1 is also localized on chromosome 9, band 9q31-32 (Zhang et al., 1998) , a region for which chromosomal gains have been observed in ACTs by CGH (Zhao et al., 1999; Sidhu et al., 2002) . KI5B encodes one of the kinesin molecular motor proteins responsible for the microtubule-dependent transport pathways in neuronal and non-neuronal cells (Goldstein, 2001) . Recently, a link between the tumor suppressor gene APC and the kinesin superfamily (Jimbo et al., 2002) has also been described.
We also found a significant increase in the expression of a subunit of protein kinase A (PKA), PRKAR2B, which is known to be involved in adrenocortical tumors (Kirschner et al., 2000; Stratakis, 2003) (Table 2 ). The increase of PRKAR2B mRNA is consistent with the augmented expression of this molecule, which we have found by real-time quantitative PCR and immunohistochemistry in AIMAH tissues . It is possible that PRKAR2B overexpression is also related to the overexpression of AKAP9 (PKA-anchoring protein 9), which was also noted (Table 2) ; this protein binds the type II regulatory subunits of PKA (Colledge and Scott, 1999) .
Supporting our results, two recent studies also raised the possibility of involvement of Wnt signaling in adrenocortical carcinomas and normal human adrenal glands. Giordano et al. (2003) studied the differential gene expression between adrenocortical carcinomas (N ¼ 11) and the benign adrenal adenomas (N ¼ 4) and hyperplasia (N ¼ 1) using Affymetrix oligonucleotide arrays. Among the genes differently expressed was the ectodermal-neural cortex 1 (ENC-1) gene that was upregulated in adrenocortical carcinomas with a 11.4-fold change compared to the benign tissues. ENC-1 is a molecular target downstream of the b-catenin/T-cell factor complex in colorectal carcinomas (Fujita et al., 2001) . Furthermore, very recently, Suwa et al. (2003) showed that various genes of the Wnt signaling pathways are expressed in the normal human adrenal cortex.
In conclusion, large-scale analysis of transcripts in nonfamilial, isolated AIMAH confirmed clinical heterogeneity and revealed several molecules and pathways that are new candidates for the investigation of adrenocortical hyperplasia. Some of these genes can be used, in the future, as clinical indices of AIMAH; in particular, WISP2 and SGNE1 may now be used as molecular markers of GIP-dependent AIMAH, as long as they are tested by RT-PCR.
Subjects and methods
Subjects
All tissue samples were obtained from patients with ACTs under research protocol 00-CH-160 approved by the Institutional Review Board of the National Institute of Child Health & Human Development, Bethesda, MD, USA and the Centre hospitalier de l'universite´de Montre´al (CHUM), Montre´al, Canada. A total of 32 adrenal samples were collected during surgery, snapfrozen and/or processed for routine histopathological examination and stored at À701C until use. Table 1 summarizes the clinical profile of the eight patients with AIMAH whose adrenocortical tissues were used for expression profiling. The clinical presentation of patients 5 and 6 has been previously described (Lacroix et al., 1997; N'Diaye et al., 1999) . In vivo screening for the detection of ectopically present receptors was performed in all patients according to a protocol that we have described elsewhere . The other adrenal tissue samples included six from other patients with AIMAH, six with ACTH-dependent adrenal hyperplasia (Cushing disease), four with Cushing syndrome caused by cortisol-producing adenoma, seven with Conn syndrome caused by aldosteroneproducing adenoma and one with adrenocortical carcinoma. As a reference sample we also included the human adrenocortical cancer cell line NCI-H295R (Rainey et al., 1994) (American Type Culture Collection (ATCC), Manassas, VA, USA). These samples were used for the validation of the microarray data (see below). The reference normal RNA sample, against which all microarray data were compared, was derived from total RNA extracted from normal adrenal glands of 62 Caucasian subjects (aged 15-61 years) and is available commercially (Clontech Laboratories, Palo Alto, CA, USA).
RNA extraction
Total RNA was isolated from frozen tissues using TRIZol Reagent s (Invitrogen, Carlsbad, CA, USA); it was further purified using the RNeasy s maxi kits (Quiagen, Inc., Valencia, CA, USA) according to the manufacturer's instructions. The quality of the RNA was evaluated by spectrophotometry and agarose gel electrophoresis.
Sample labeling and hybridization
Total RNA (20 mg) was used for each experiment. Labeling was performed by reverse transcription reaction with green fluorescent cyanine 3-dUTP and red fluorescent cyanine 5-dUTP using the MICROMAX direct cDNA microarray system (NENPerkin Elmer Life Sciences Inc., Boston, MA, USA). Samples (specimen and normal) were combined, purified and concentrated with Microcon YM30 columns (Millipore Corp., Bedford, MA, USA). After denaturation, probes were hybridized at 651C for 16 h to a microarray glass slide that was made at the National Cancer Institute (Bethesda, MD, USA) core facility containing approximately 10 000 human PCR-amplified cDNA clones. Slides were then washed in 0.5 Â SSC, 0.01% SDS for 10 min; 0.06 Â SSC, 0.01% SDS for 10 min and 0.06 Â SSC for 5 min and scanned on a dual-laser microarray scanner (GenePix 4000; Axon Instruments, Foster City, CA, USA). The experiments were repeated an average of three times per sample including reciprocal labeling of fluochromes. The images were analysed by GenePix Pro 3.0 (Axon Instruments Inc.). Data were imported in the National Cancer Institute Center for Information Technology Microarray database (NCI-CIT mArray). For quality control, a self-hybridization study was conducted in duplicate in which 20 mg of total RNA of normal adrenal glands was labeled with Cye5 and Cye3, respectively, and cohybridized on the microarray slide.
Microarray data analysis
Scanned hybridization images were inspected for artifacts and other defects; all spots with defective hybridization were then excluded. The Cye3 and Cye5 fluorescent intensities and background values were obtained for each individual spot using the GenePix 4000 microarray software (Axon Instruments). For each spot, the signal intensities were determined by the following formula: (mean spot intensities)À(median background intensities).
To validate the data, we performed self-hybridization study of total RNA from our pool of normal adrenal glands. We showed that the variation of the ratio is less than twofold for 99.7% of genes having signal intensities greater than 1000 pixels in at least one channel. These were the stringent criteria that we selected for the analysis of all the data from our samples; then, only spots with signal intensities X1000 pixels (after background subtraction) in at least one channel were included. We empirically determined the significance cutoff for signal : background ratio as 1.5 in both channels. For each spot, the average ratios from replicates were calculated for individual samples. Each slide was normalized based on the information available at the NCI-CIT mArray site (http://nciarray.nci.nih.gov) in order to minimize the intersample variation for the efficiency of Cye5 and Cye3 labeling.
Multiplex RT-PCR
Total RNA was extracted from adrenal samples by standard methods, as described above. First-strand cDNA synthesis was carried out with 2 mg total RNA and random primers (hexamers) using Moloney murine leukemia virus (MMLV) RT (Life Technologies, Burlington, Canada) as recommended by the manufacturer. The primers that were used were located in two different exons of each gene to circumvent amplification of any contaminating genomic DNA; in addition, a control reaction, without RT was performed. The RT-PCR reaction was terminated when all samples were in the linear range of amplification. Thus, for each selected gene transcripts, reactions were performed with a pool of cDNA of normal adrenals; one tube was removed every four cycles, starting from the 12th cycle. The PCR products were then subjected to electrophoresis on an agarose 1.5% gel and visualized by ethidium bromide staining. The bands were detected by PhosphorImaget and quantified by ImageQuantt. The cycle number was plotted against the log of the signal and a straight line was obtained for samples in the linear range of amplification; the midpoint of the linear part of the curve was then chosen. Finally, a multiplex PCR was performed using two sets of primers, the first to amplify the cDNA of interest and the second to amplify an endogenous control (18S rRNA -QuantumRNAt 18S internal standards, Ambion Inc., Austin, TX, USA). The sequence of the oligonucleotide primers and the exact PCR conditions for each gene of interest are available on request.
Analysis of the RT-PCR data
For analysis, the band density produced from the amplification of the gene of interest was normalized against that of the product of the endogenous control. In order to obtain a similar amplicon between the two PCR products, the efficiency of rRNA 18S amplification was adjusted choosing the best primers-to-'competimers' ratio. Each gene had its expression assessed at least two times in order to confirm reproducibility; the mean value of these two experiments was taken as the final value for each analysis.
The results are expressed as the mean7standard error of the mean (s.e.m.). For all analysis, we used Student's t-test; a P-value of less than 0.05 was considered significant in all experiments.
